{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:11:12Z","timestamp":1791288672646,"version":"4.3.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,15]]},"DOI":"10.1093\/cid\/ciu773","type":"journal-article","created":{"date-parts":[[2014,10,4]],"date-time":"2014-10-04T05:52:19Z","timestamp":1412401939000},"page":"311-317","source":"Crossref","is-referenced-by-count":57,"title":["Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control"],"prefix":"10.1093","volume":"60","author":[{"given":"Andrea","family":"Calcagno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Simiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Alberione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Bracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Marinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ecclesia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Perri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,10,3]]},"reference":[{"key":"key\n\t\t\t\t20170522094415_CIU773C1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/WCO.0b013e32834695fb","article-title":"Current understanding of HIV-associated neurocognitive disorders pathogenesis","volume":"24","year":"2011","journal-title":"Curr Opin Neurol"},{"key":"key\n\t\t\t\t20170522094415_CIU773C2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1473-3099(13)70269-X","article-title":"HIV-associated neurocognitive disorder","volume":"13","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170522094415_CIU773C3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/aje\/kwu098","article-title":"The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV","volume":"180","year":"2014","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20170522094415_CIU773C4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3851\/IMP2560","article-title":"Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia","volume":"18","year":"2013","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170522094415_CIU773C5","doi-asserted-by":"crossref","first-page":"e6877","DOI":"10.1371\/journal.pone.0006877","article-title":"Raltegravir cerebrospinal fluid concentrations in HIV-1 infection","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522094415_CIU773C6","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1128\/AAC.00507-10","article-title":"Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094415_CIU773C7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jac\/dkt339","article-title":"High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis","volume":"69","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522094415_CIU773C8","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1128\/AAC.00691-12","article-title":"Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522094415_CIU773C9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/jac\/dkr490","article-title":"Pharmacokinetics and inhibitory quotient of atazanavir\/ritonavir versus lopinavir\/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE study","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522094415_CIU773C10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/jac\/dkq384","article-title":"Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens","volume":"66","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522094415_CIU773C11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchromb.2007.10.003","article-title":"HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients","volume":"859","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"key\n\t\t\t\t20170522094415_CIU773C12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/QAI.0b013e318274e2b0","article-title":"Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid","volume":"62","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522094415_CIU773C13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000000096","article-title":"Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?","volume":"28","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522094415_CIU773C14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/jac\/dkr492","article-title":"Antiretroviral drug treatment of CNS HIV-1 infection","volume":"67","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522094415_CIU773C15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/QAD.0b013e3283553619","article-title":"Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics","volume":"26","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522094415_CIU773C16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/QAD.0b013e328317a702","article-title":"Low atazanavir concentrations in cerebrospinal fluid","volume":"23","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522094415_CIU773C17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/jac\/dks517","article-title":"Etravirine in CSF is highly protein bound","volume":"68","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522094415_CIU773C18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FTD.0b013e31824aa50a","article-title":"Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting","volume":"34","year":"2012","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t20170522094415_CIU773C19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/650538","article-title":"Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522094415_CIU773C20","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/QAD.0b013e328355e6b2","article-title":"Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load","volume":"26","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522094415_CIU773C21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/QAD.0b013e3283489cb1","article-title":"Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brain barrier damage","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522094415_CIU773C22","article-title":"CSF-serum albumin ratios are associated with neurocognitive impairment in antiretroviral-treated people with HIV"},{"key":"key\n\t\t\t\t20170522094415_CIU773C23","doi-asserted-by":"crossref","first-page":"e70164","DOI":"10.1371\/journal.pone.0070164","article-title":"HIV DNA reservoir increases risk for cognitive disorders in cART-naive patients","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522094415_CIU773C24","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1086\/657342","article-title":"HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment","volume":"202","year":"2010","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T21:49:21Z","timestamp":1498168161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciu773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,3]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,10,3]]},"published-print":{"date-parts":[[2015,1,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciu773","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,3]]}}}